Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.

Published

Journal Article

We report on 348 patients ≥ 70 years (median age 78 years) with acute myeloid leukemia (>50% with secondary AML) randomized to receive either 600 mg or 300 mg of tipifarnib orally twice daily on days 1-21 or days 1-7 and 15-21, repeated every 28 days (4 treatment regimens). Responses were seen in all regimens, with overall response rate (CR + CRi + PR) highest (20%) among patients receiving tipifarnib 300 mg twice daily on days 1-21. Toxicities were acceptable. Unless predictors of response to tipifarnib are identified, further study as a single agent in this population is unwarranted.

Full Text

Duke Authors

Cited Authors

  • Erba, HP; Othus, M; Walter, RB; Kirschbaum, MH; Tallman, MS; Larson, RA; Slovak, ML; Kopecky, KJ; Gundacker, HM; Appelbaum, FR

Published Date

  • March 2014

Published In

Volume / Issue

  • 38 / 3

Start / End Page

  • 329 - 333

PubMed ID

  • 24411921

Pubmed Central ID

  • 24411921

Electronic International Standard Serial Number (EISSN)

  • 1873-5835

Digital Object Identifier (DOI)

  • 10.1016/j.leukres.2013.12.001

Language

  • eng

Conference Location

  • England